AstraZeneca Canada’s Calquence (acalabrutinib) Receives Health Canada Approval for Patients Previously Treated with Mantle Cell Lymphoma (MCL)

AstraZeneca Signs a License Agreement with Theragnostics for its PARP Inhibitor


  • The NOC is based on the positive data of Calquence in ACE-LY-004 trial demonstrating 81% OR rate for patients with relapsed or refractory MCL
  • The Health Canada approval of Calquence allows AstraZeneca to develop the treatments of blood cancers
  • Calquence (acalabrutinib, previously known as ACP-196) is an oral selective inhibitor of Bruton’s tyrosine kinase (BTK) which further irreversibly binds to it while inhibiting its activity, with its recommended dose one 100mg capsule administered twice daily

Click here to­ read full press release/ article | Ref: Newswire | Image: Twitter